$INCY News
Last published 1d ago
- 1d agoNTRAINCYNatera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal CancerBusiness WireAUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with Incyte (Nasdaq:INCY) for a new phase II study in colorectal cancer (CRC). The trial will evaluate INCA33890, Incyte’s investigational bispecific immunotherapy, in patients with stage 2/3 CRC who have co ...
- 1w agoINCYINCYTE CORP - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoINCYIncyte Reports Third Quarter 2026 Financial Results and Provides Business UpdatesBusiness WireTotal revenue of $1.56 billion and total net sales of $1.32 billion in the third quarter of 2026, each an increase of 14% compared to the third quarter of 2025 Jakafi®/Jakafi XR™ (ruxolitinib) net sales of $827
- 2w agoINCYIncyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026Business WireINCB161734 (KRAS G12D inhibitor) and INCA338901 (TGFβR2×PD-1 bispecific antibody) data reinforce ongoing and planned registrational trials, including DAWN-303 in pancreatic ductal adenocarcinoma (PDAC) and NEXERA-303
- 2w agoGMABINCYGenmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal CancerBusiness WirePhase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Genmab A/S (NASDAQ:GMAB) and Incyte (NASDAQ:INCY)
- 2w agoINCYGMABIncyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal CancerBusiness WirePhase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Incyte (NASDAQ:INCY) and Genmab A/S (NASDAQ:GMAB) today
- 3w agoINCYIncyte to Highlight Key Oncology Data Presentations at the European Society for Medical Oncology (ESMO) Congress 2026Business WireFour rapid oral presentations at ESMO will feature new data for INCB161734, a KRAS G12D inhibitor, and INCA338901, a TGFβR2×PD-1 bispecific antibody Both investigational therapies are being evaluated in ongoing Phase
- 1mo agoINCYIncyte to Report Third Quarter Financial ResultsBusiness WireIncyte (NASDAQ:INCY) announced today that it has scheduled its third quarter financial results conference call and webcast for 8:00 a.m. ET on Thursday, October 29, 2026. The schedule for the press release and
- 1mo agoMIRMINCYMirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans ProgressivaBusiness Wire-Once-daily oral ALK2 inhibitor approved to reduce the volume of total new heterotopic ossification in patients aged 12 years and older with FOP -Atebrioz expected to be available in the United States in October
- 1mo agoINCYApproval of Atebrioz, Nda #221198 (Type 1 - New Molecular Entity)FDA Approved DrugsApproval Date: 09/25/2026; Drug Name: Atebrioz, Nda #221198; Active Ingredients: ZILURGISERTIB; Company: Incyte Corp; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity; Application Number: 221198
- 1mo agoINCYIncyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity PortfolioBusiness WireIncyte (NASDAQ:INCY) today announced that data from across its Inflammation and Autoimmunity (IAI) portfolio will be presented at the European Academy of Dermatology and Venereology (EADV) 2026, held September 30 -
- 1mo agoINCYSpecialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in AustraliaPR NewswireIndependent biopharmaceutical company Specialised Therapeutics (ST) today announced an expansion of its existing partnership with Incyte Biosciences...
- 2mo agoINCYIncyte to Present at Upcoming Investor ConferencesBusiness WireIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of September: 21st Annual Wells Fargo Healthcare Conference on Wednesday, September 9, 2026 at 11:00
- 2mo agoINCYKnight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in BrazilGlobeNewswireMONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX:GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to
- 3mo agoINCYIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireIncyte Corporation (NASDAQ:INCY) announced today that it granted restricted stock unit awards (RSUs) representing an aggregate of 21,556 shares of the Company’s common stock and stock option awards to purchase an
- 3mo agoINCYNew Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBSPR NewswireIndependent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the listing of Minjuvi® (tafasitamab), in combination with ...
- 3mo agoINCYOpzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic DermatitisBusiness WireThe European Commission approval is based on Phase 3b TRuE‑AD4 data which demonstrated that Opzelura® (ruxolitinib) cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment
- 3mo agoINCYIncyte Reports Second Quarter 2026 Financial Results and Provides Business UpdatesBusiness WireTotal revenue of $1.67 billion and total net sales of $1.49 billion in the second quarter of 2026, an increase of 38% and 40%, respectively, compared to the second quarter of 2025 Total net sales, excluding the
- 3mo agoHALOINCYHalozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® TechnologyPR NewswireHalozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has entered into a global collaboration and license...
- 3mo agoINCYApproval of Jakafi, Nda #202192 (Labeling)FDA Approved DrugsApproval Date: 07/20/2026; Drug Name: Jakafi, Nda #202192; Active Ingredients: RUXOLITINIB PHOSPHATE; Company: Incyte Corp; Submission Status: Approval; Submission Classification: Labeling; Application Number: 202192
- 3mo agoINCYApproval of Jakafi Xr, Nda #217180 (Labeling)FDA Approved DrugsApproval Date: 07/20/2026; Drug Name: Jakafi Xr, Nda #217180; Active Ingredients: RUXOLITINIB PHOSPHATE; Company: Incyte Corp; Submission Status: Approval; Submission Classification: Labeling; Application Number: 217180
- 3mo agoINCYIncyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat CancersBusiness WireRapid oral presentations will highlight new Phase 1 data across Incyte’s solid tumor portfolio Both INCB161734, an investigational, potent, selective and orally bioavailable KRAS G12D inhibitor, and INCA338901, a
- 4mo agoINCYIncyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease TypesBusiness Wire- Treatment with latarcibart led to an 81% median reduction in annualized bleeding rate (ABR) across all bleeding categories and patient types with von Willebrand disease (VWD) - Latarcibart, administered via a once
- 4mo agoINCYIncyte to Report Second Quarter Financial ResultsBusiness WireIncyte (NASDAQ:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 28, 2026. The schedule for the press release and
- 4mo agoINCYIncyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology PortfolioBusiness WireAcquisition adds VGA039, a novel investigational monoclonal antibody in Phase 3 development for patients with von Willebrand disease (VWD), strengthening Incyte’s late-stage pipeline Incyte (NASDAQ:INCY) announced
- 4mo agoINCYStar Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 CongressBusiness WireStar Therapeutics, a late clinical-stage biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need, today announced an upcoming oral presentation
- 4mo agoINCYIncyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic DermatitisBusiness WireIf approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies
- 4mo agoINCYIncyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Business WireIncyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or
- 5mo agoINCYMIRMMirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans ProgressivaBusiness Wire- Cohort 1 results presented at ENDO 2026 demonstrate meaningful reductions in total heterotopic ossification (HO) lesion volume, new HO lesions and flare activity in adolescents and adults with FOP - U.S. Food and
- 5mo agoINCYIncyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential ThrombocythemiaBusiness WireIn myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with
- 5mo agoINCYResults from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free SurvivalBusiness Wire- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the
- 5mo agoINCYIncyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding DisordersBusiness Wire- Proposed acquisition to add VGA039, a novel investigational monoclonal antibody that targets Protein S in Phase 3 development for von Willebrand disease (VWD) - Star Therapeutics to receive $1.25 billion upfront,
- 5mo agoINCYMIRMMirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026Business Wire- Late-breaking rapid-fire presentation to include results from Cohort 1 of the placebo-controlled PROGRESS study evaluating zilurgisertib in fibrodysplasia ossificans progressiva (FOP) Mirum Pharmaceuticals, Inc.
- 5mo agoINCYIncyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCLBusiness WireThe Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated
- 5mo agoINCYIncyte to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceBusiness WireIncyte (NASDAQ:INCY) announced today that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 8:40 a.m. EDT. The presentation will be webcast live and can be
- 5mo agoINCYIncyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug DiscoveryBusiness WireThe expanded agreement is one of the first major Pharma-AI collaborations to power large-scale foundation model training with a partner's proprietary experimental data Incyte data will be securely used to train
- 5mo agoINCYIncyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and DevelopmentBusiness WireIncyte (NASDAQ:INCY) and Edison Scientific today announced a strategic collaboration to employ Kosmos, Edison's AI scientist, for Incyte's discovery and development work. This press release features multimedia. View
- 5mo agoINCYApproval of Zynyz, Bla #761334FDA Approved DrugsApproval Date: 05/18/2026; Drug Name: Zynyz, Bla #761334; Active Ingredients: RETIFANLIMAB-DLWR; Company: Incyte Corp; Submission Status: Approval; Application Number: 761334
- 6mo agoINCYIncyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 CongressBusiness WireData from pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) selected for prestigious Plenary Abstracts Session Oral and poster
- 6mo agoINCYIncyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic DermatitisBusiness WireFirst presentation of Week 24 results from TRuE-AD4 study in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance or contraindication to topical corticosteroids (TCSs) and topical
- 6mo agoINCYIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireIncyte Corporation (NASDAQ:INCY) announced today that it granted equity inducement awards to Suketu (Suky) Upadhyay, the Company's new Executive Vice President and Chief Financial Officer, pursuant to the Company's 2024
- 6mo agoINCYNew First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]PR NewswireIndependent biopharmaceutical company Specialised Therapeutics is pleased to announce that NIKTIMVO® (axatilimab) has been approved for use in...
- 6mo agoINCYIncyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host DiseaseBusiness WireJakafi XR is a once-daily, film-coated, extended-release formulation of Jakafi® (ruxolitinib) Once-daily Jakafi XR was shown to provide consistent, day-long exposure comparable to twice-daily Jakafi Jakafi
- 6mo agoINCYApproval of Jakafi Xr, Nda #217180 (Type 5 - New Formulation or New Manufacturer)FDA Approved DrugsApproval Date: 05/01/2026; Drug Name: Jakafi Xr, Nda #217180; Active Ingredients: RUXOLITINIB PHOSPHATE; Company: Incyte Corporation; Submission Status: Approval; Submission Classification: Type 5 - New Formulation or New Manufacturer; Application Number: 217180
- 6mo agoINCYIncyte to Present at Upcoming Investor ConferencesBusiness WireIncyte (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of May: BofA Securities 2026 Health Care Conference on Wednesday, May 13, 2026 at 1:40 pm (PDT)
- 6mo agoINCYIncyte Appoints Suketu (Suky) Upadhyay as Chief Financial OfficerBusiness WireIncyte (NASDAQ:INCY) announces the appointment of Suketu (Suky) Upadhyay as Executive Vice President and Chief Financial Officer (CFO) effective May 4, 2026. In his new role, Mr. Upadhyay will serve as a key member of
- 6mo agoINCYIncyte Reports First Quarter 2026 Financial Results and Provides Business UpdatesBusiness WireTotal revenue of $1.27 billion and total net sales of $1.10 billion in the first quarter of 2026, an increase of 21% and 20% respectively, compared to the first quarter of 2025 Jakafi® (ruxolitinib) net sales of
- 6mo agoINCYMINJUVI® (tafasitamab) for Relapsed or Refractory Follicular Lymphoma Approved in AustraliaPR NewswireIndependent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that Minjuvi® (tafasitamab), in combination with rituximab ...
- 6mo agoINCYIncyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingBusiness Wire- Data from pivotal frontMIND study of tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) featured in oral presentation at ASCO; results support global regulatory
- 7mo agoINCYIncyte to Report First Quarter Financial ResultsBusiness WireIncyte (NASDAQ:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 28, 2026. The schedule for the press release and conference